FDA recommends bringing controversial IBS drug back.
McCarthy
Michael
M
D002243:Carbolines / Q000627:therapeutic use*; D003109:Colonic Diseases, Functional / Q000188:drug therapy*; D017277:Drug Approval / Q000331:legislation & jurisprudence; D006801:Humans; D012702:Serotonin Antagonists / Q000627:therapeutic use*; D014481:United States; D014486:United States Food and Drug Administration / Q000331:legislation & jurisprudence*
D002243:Carbolines; D012702:Serotonin Antagonists; C090840:alosetron